Figure 3. The results of meta-analysis of association between BIM deletion polymorphism and progression-free, overall survival in malignancy with kinase inhibitor therapy.
(A) BIM deletion polymorphism and progression-free survival; (B) BIM deletion polymorphism and overall survival.